Terns Pharmaceuticals (TERN) Competitors $3.73 -0.10 (-2.61%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. EVO, MESO, VERA, OCUL, TVTX, BGM, GPCR, CVAC, CALT, and DYNShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Evotec (EVO), Mesoblast (MESO), Vera Therapeutics (VERA), Ocular Therapeutix (OCUL), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Evotec Mesoblast Vera Therapeutics Ocular Therapeutix Travere Therapeutics BGM Group Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Dyne Therapeutics Evotec (NASDAQ:EVO) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment. Do insiders and institutionals have more ownership in EVO or TERN? 5.8% of Evotec shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, EVO or TERN? Terns Pharmaceuticals has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.73-$212.18MN/AN/ATerns PharmaceuticalsN/AN/A-$88.85M-$1.09-3.42 Is EVO or TERN more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% Terns Pharmaceuticals N/A -28.81%-27.55% Does the media prefer EVO or TERN? In the previous week, Terns Pharmaceuticals had 4 more articles in the media than Evotec. MarketBeat recorded 6 mentions for Terns Pharmaceuticals and 2 mentions for Evotec. Evotec's average media sentiment score of 0.94 beat Terns Pharmaceuticals' score of 0.87 indicating that Evotec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend EVO or TERN? Evotec currently has a consensus price target of $5.93, suggesting a potential upside of 41.27%. Terns Pharmaceuticals has a consensus price target of $15.63, suggesting a potential upside of 318.90%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, EVO or TERN? Evotec has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. SummaryTerns Pharmaceuticals beats Evotec on 8 of the 13 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$325.78M$2.82B$5.46B$8.91BDividend YieldN/A2.71%5.36%4.15%P/E Ratio-3.4221.2926.4619.70Price / SalesN/A251.58404.54108.31Price / CashN/A41.2925.8827.49Price / Book0.927.247.925.42Net Income-$88.85M-$55.05M$3.15B$248.34M7 Day Performance1.36%1.83%2.20%2.41%1 Month Performance19.55%6.06%4.39%4.80%1 Year Performance-45.23%0.66%32.26%17.50% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals4.1992 of 5 stars$3.73-2.6%$15.63+318.9%-43.8%$325.78MN/A-3.4240EVOEvotec1.4905 of 5 stars$3.81+1.3%$5.93+55.7%-13.3%$1.34B$862.40M0.004,827Gap UpMESOMesoblast1.8828 of 5 stars$10.16-2.7%$18.00+77.2%+60.4%$1.33B$5.90M0.0080VERAVera Therapeutics3.4961 of 5 stars$21.65+3.8%$65.00+200.2%-37.4%$1.33BN/A-7.2240Positive NewsOCULOcular Therapeutix3.8569 of 5 stars$8.37+3.0%$17.33+107.1%+34.8%$1.30B$63.72M-7.28230TVTXTravere Therapeutics3.0238 of 5 stars$14.49+1.3%$32.14+121.8%+79.7%$1.27B$233.18M-5.16460BGMBGM GroupN/A$13.12+0.4%N/AN/A$1.27B$25.10M0.00298News CoverageAnalyst UpgradeHigh Trading VolumeGPCRStructure Therapeutics2.6051 of 5 stars$22.10+1.7%$76.17+244.6%-46.3%$1.25BN/A-25.40136High Trading VolumeCVACCureVac4.661 of 5 stars$5.39-0.9%$9.00+67.0%+58.2%$1.22B$579.18M5.86880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DYNDyne Therapeutics3.6384 of 5 stars$10.16-1.6%$43.93+332.4%-72.9%$1.17BN/A-2.83100 Related Companies and Tools Related Companies Evotec Competitors Mesoblast Competitors Vera Therapeutics Competitors Ocular Therapeutix Competitors Travere Therapeutics Competitors BGM Group Competitors Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Dyne Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
